Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on December 4, 2012, covering events occurring on November 29, 2012. The filing addresses an amendment to a services agreement with a key consultant.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to a specific consulting arrangement:
- Monthly Services Fee: $15,880.40
- Consulting Time Commitment: 50% of business time
Material Changes
The Company entered into Amendment #2 to the Services Agreement with MPM Asset Management LLC and Gary Patou. This amendment reversed a previously scheduled reduction in consulting services and fees:
- Previous Plan: Reduce time commitment from 50% to 20% and monthly fee from $15,880.40 to $6,352.16 starting in 2013.
- Amended Terms: Maintain 50% time commitment and the $15,880.40 monthly fee through December 31, 2013.
Outlook, Risks, and Management Commentary
Management, specifically the Compensation and Audit Committees, approved the amendment to retain the current level of consulting services. The filing does not contain forward-looking guidance, risk factors, or discussion of unusual items beyond this contractual change.
Key Facts for Investor Verification
- Verify the total annual cost of the amended agreement ($15,880.40 x 12 months) relative to the company's cash position.
- Confirm the specific roles and deliverables of Gary Patou and MPM Asset Management LLC to justify the 50% time commitment.
- Review the full text of Exhibit 99.1 (Amendment #2) for termination clauses or additional compensation terms not summarized in the 8-K.